Trial reportScientific reports2026
Oleoylethanolamide supplementation improves mood and reduces fatigue in veterans with GWI in a 15-week randomized, double-blind, placebo-controlled exploratory clinical trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05252949 (A Randomized, Double-blind, Placebo-controlled Clinical Trial of Oleoylethanolamide), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Oleoylethanolamide (OEA) for Targeting Lipid Metabolism in Gulf War Illness
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Gulf War Illness (GWI) affects 32% of Veterans from the 1990-1991 Gulf War. It is characterized by fatigue, mood disturbances, pain and cognitive decrements, with no FDA-approved treatment. This exploratory randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of oleoylethanolamide (OEA) supplementation in 52 Veterans with GWI (mean age 59 ± 5 SD, 94% males and 79% White). Participants received 200 mg of OEA twice daily or a matching placebo for 10 weeks, followed by a 5-week open-label OEA extension. Outcomes included the Multidimensional Fatigue Inventory (MFI-20), abbreviated Profile of Mood States (POMS), Short-Form McGill Pain Questionnaire, Veterans RAND 36-Item Health Survey (SF-36 V), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and CNS Vital Signs Test, administered at baseline and 10- and 15-weeks. A main effect of OEA for reducing fatigue (MFI-20, p ≤ 0.05) and improving the total mood disturbances score (POMS, p ≤ 0.05) was observed. Participants on OEA reported increased energy, emotional well-being, and social functioning (SF-36 V, p ≤ 0.05). No changes were seen in cognitive performance or pain. Oleoylethanolamide was well-tolerated with no serious adverse events. In summary, OEA was safe and improved fatigue and mood in Veterans with GWI. Larger trials are needed to confirm these benefits.Registered under ClinicalTrials.gov Identifier no. NCT05252949 (first posted date: 23/02/2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.